{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:28:42Z","timestamp":1772166522355,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T00:00:00Z","timestamp":1583539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T00:00:00Z","timestamp":1583539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Programmed death-1 (PD-1) and its ligand PD-L1 are now used as predictive biomarkers to guide clinical decisions. Precise characterization of PD-L1-positive cells may contribute to our knowledge of which patients derive benefit from the PD-L1 blockade therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>To address this issue, we performed immunophenotyping of PD-L1-positive cells in Hodgkin lymphoma and in angioimmunoblastic T cell lymphoma (AITL) employing multiple immunofluorescent immunolabeling. We found that PD-L1-positive cells and PD-1-positive cells both in Hodgkin lymphoma and in AITL belong to two completely different cell lineages. In both lymphomas, PD-1 was found exclusively in T-lymphocytes, whereas PD-L1 was revealed in the tumor microenvironment cells including macrophages. PD-L1 was also detected in CD30-positive cells in Hodgkin lymphoma but not in AITL. The marker of B-cell lineage, CD20, was not detectable in PD-L1-positive cells both in AITL and in Hodgkin. Our study highlights the importance of comprehensive assessment of PD-1\/PD-L1 regulatory pathways for employing PD-L1 as a predictive biomarker in clinical practice. PD-L1-antibody therapy is proven in Hodgkin lymphoma. Comparative immunophenotyping of the PD-1\/PD-L1 axis provides a support for attempts to prove this principle also for AITL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-020-04975-w","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T19:04:18Z","timestamp":1583521458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Markus","family":"Tiemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Samoilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitri","family":"Atiakshin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Buchwalow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,7]]},"reference":[{"issue":"11","key":"4975_CR1","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887\u201395.","journal-title":"EMBO J"},{"issue":"1","key":"4975_CR2","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2017;7(1):e1364828.","journal-title":"Oncoimmunology"},{"issue":"12","key":"4975_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365\u20139.","journal-title":"Nat Med"},{"issue":"21","key":"4975_CR4","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","volume":"130","author":"WR Liu","year":"2017","unstructured":"Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood. 2017;130(21):2265\u201370.","journal-title":"Blood"},{"issue":"4","key":"4975_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203\u201320.","journal-title":"Nat Rev Clin Oncol."},{"key":"4975_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","volume":"71","author":"PK Panjwani","year":"2018","unstructured":"Panjwani PK, Charu V, DeLisser M, Molina-Kirsch H, Natkunam Y, Zhao S. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol. 2018;71:91\u20139.","journal-title":"Hum Pathol"},{"key":"4975_CR7","doi-asserted-by":"publisher","first-page":"36956","DOI":"10.1038\/srep36956","volume":"6","author":"HR Kim","year":"2016","unstructured":"Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW, Choi EC, Kim EK, Pyo KH, Jung I, Seo D, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep. 2016;6:36956.","journal-title":"Sci Rep."},{"issue":"49","key":"4975_CR8","doi-asserted-by":"publisher","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004;101(49):17174\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"4975_CR9","doi-asserted-by":"publisher","first-page":"e0157176","DOI":"10.1371\/journal.pone.0157176","volume":"11","author":"N Maekawa","year":"2016","unstructured":"Maekawa N, Konnai S, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Takagi S, Kagawa Y, Nakajima C, Suzuki Y, et al. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. PLoS ONE. 2016;11(6):e0157176.","journal-title":"PLoS ONE"},{"issue":"22","key":"4975_CR10","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","volume":"125","author":"P Armand","year":"2015","unstructured":"Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125(22):3393\u2013400.","journal-title":"Blood"},{"issue":"9","key":"4975_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3324\/haematol.2015.129650","volume":"100","author":"N Kekre","year":"2015","unstructured":"Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, et al. Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015;100(9):1222\u20137.","journal-title":"Haematologica"},{"key":"4975_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2016","unstructured":"Goodman A, Patel SP, Kurzrock R. PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2016;14:203.","journal-title":"Nat Rev Clin Oncol."},{"issue":"23","key":"4975_CR13","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1182\/blood.V126.23.3899.3899","volume":"126","author":"Z Gatalica","year":"2015","unstructured":"Gatalica Z, Bilalovic N, Vranic S, Arguello D, Reddy S, Ghosh N. PD-L1 and PD1 expression in lymphomas. Blood. 2015;126(23):3899.","journal-title":"Blood"},{"key":"4975_CR14","doi-asserted-by":"publisher","first-page":"13110","DOI":"10.1038\/srep13110","volume":"5","author":"J He","year":"2015","unstructured":"He J, Hu Y, Hu M, Li B. Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 2015;5:13110.","journal-title":"Sci Rep"},{"issue":"8","key":"4975_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","volume":"25","author":"KM Zak","year":"2017","unstructured":"Zak KM, Grudnik P, Magiera K, D\u00f6mling A, Dubin G, Holak TA. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2. Structure.\u00a02017;25(8):1163\u201374.","journal-title":"Structure."},{"issue":"1","key":"4975_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68\u201383.","journal-title":"Blood"},{"issue":"6","key":"4975_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/imt-2016-0150","volume":"9","author":"PN Aguiar Jr","year":"2017","unstructured":"Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H, Lima Lopes GD. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy. 2017;9(6):499\u2013506.","journal-title":"Immunotherapy."},{"issue":"2","key":"4975_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207\u201312.","journal-title":"Curr Opin Immunol"},{"issue":"26","key":"4975_CR19","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"1","key":"4975_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.15690\/onco.v4i1.1684","volume":"4","author":"Y Klyuchagina","year":"2017","unstructured":"Klyuchagina Y, Sokolova Z, Baryshnikova M. Role of PD-1 receptor and its ligands PD-L1 and PD-L2 in cancer immunotherapy. Onkopediatria. 2017;4(1):49\u201355.","journal-title":"Onkopediatria."},{"issue":"4","key":"4975_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356.","journal-title":"Mol Cancer Ther"},{"key":"4975_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.","journal-title":"Front Pharmacol."},{"key":"4975_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.critrevonc.2018.07.010","volume":"130","author":"T Fujii","year":"2018","unstructured":"Fujii T, Naing A, Rolfo C, Hajjar J. Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2018;130:108\u201320.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4975_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-017-0479-y","volume":"10","author":"D Liu","year":"2017","unstructured":"Liu D, Wang S, Bindeman W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol. 2017;10(1):110.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4975_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","volume":"39","author":"HU Schildhaus","year":"2018","unstructured":"Schildhaus HU. Predictive value of PD-L1 diagnostics. Pathologe. 2018;39(6):498\u2013519.","journal-title":"Pathologe"},{"issue":"Suppl 1","key":"4975_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1023\/A:1008383406103","volume":"11","author":"NL Harris","year":"2000","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification\u2013from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol. 2000;11(Suppl 1):3\u201310.","journal-title":"Ann Oncol"},{"issue":"2","key":"4975_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s002920050377","volume":"21","author":"H Stein","year":"2000","unstructured":"Stein H. The new WHO classification of malignant lymphoma. After \u201cREAL\u201d a further step on the road to a worldwide consensus. Pathologe. 2000;21(2):101\u20135.","journal-title":"Pathologe."},{"key":"4975_CR28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/srep00028","volume":"1","author":"I Buchwalow","year":"2011","unstructured":"Buchwalow I, Samoilova V, Boecker W, Tiemann M. Non-specific binding of antibodies in immunohistochemistry: fallacies and facts. Sci Rep. 2011;1:28.","journal-title":"Sci Rep."},{"key":"4975_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-04609-4","volume-title":"Immunohistochemistry: basics and methods","author":"IB Buchwalow","year":"2010","unstructured":"Buchwalow IB, Boecker W. Immunohistochemistry: basics and methods. 1st ed. Heidelberg: Springer; 2010.","edition":"1"},{"issue":"2","key":"4975_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00418-017-1624-y","volume":"149","author":"I Buchwalow","year":"2018","unstructured":"Buchwalow I, Atiakshin D, Samoilova V, Boecker W, Tiemann M. Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma. Histochem Cell Biol. 2018;149(2):169\u201377.","journal-title":"Histochem Cell Biol"},{"issue":"8","key":"4975_CR31","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/modpathol.2013.45","volume":"26","author":"W Boecker","year":"2013","unstructured":"Boecker W, Stenman G, Loening T, Andersson MK, Bankfalvi A, von Holstein S, Heegaard S, Lange A, Berg T, Samoilova V, et al. K5\/K14-positive cells contribute to salivary gland-like breast tumors with myoepithelial differentiation. Mod Pathol. 2013;26(8):1086\u2013100.","journal-title":"Mod Pathol"},{"issue":"5","key":"4975_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.acthis.2018.05.002","volume":"120","author":"I Buchwalow","year":"2018","unstructured":"Buchwalow I, Samoilova V, Boecker W, Tiemann M. Multiple immunolabeling with antibodies from the same host species in combination with tyramide signal amplification. Acta Histochem. 2018;120(5):405\u201311.","journal-title":"Acta Histochem"},{"issue":"7","key":"4975_CR33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/labinvest.2017.37","volume":"97","author":"W Zhang","year":"2017","unstructured":"Zhang W, Hubbard A, Jones T, Racolta A, Bhaumik S, Cummins N, Zhang L, Garsha K, Ventura F, Lefever MR, et al. Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies. Lab Invest. 2017;97(7):873\u201385.","journal-title":"Lab Invest"},{"issue":"6","key":"4975_CR34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11899-016-0345-y","volume":"11","author":"G Bhatt","year":"2016","unstructured":"Bhatt G, Maddocks K, Christian B. CD30 and CD30-targeted therapies in hodgkin lymphoma and other B cell lymphomas. Curr Hematol Malig Rep. 2016;11(6):480\u201391.","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"4975_CR35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1046\/j.1365-2141.2001.02977.x","volume":"114","author":"D Molin","year":"2001","unstructured":"Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson K, Sundstrom C, Enblad G, Nilsson G. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin\u2019s disease. Br J Haematol. 2001;114(3):616\u201323.","journal-title":"Br J Haematol"},{"issue":"23","key":"4975_CR36","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4975_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/PAS.0000000000000571","volume":"40","author":"A Onaindia","year":"2016","unstructured":"Onaindia A, Mart\u00ednez N, Montes-Moreno S, Almaraz C, Rodr\u00edguez-Pinilla SM, Cereceda L, Revert JB, Ortega C, Tardio A, Gonz\u00e1lez L, et al. CD30 expression by B and T cells: a frequent finding in angioimmunoblastic T-Cell lymphoma and peripheral T-cell lymphoma-not otherwise specified. Am J Surg Pathol. 2016;40(3):378\u201385.","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"4975_CR38","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.5858\/2010-0207-OA.1","volume":"134","author":"LB Smith","year":"2010","unstructured":"Smith LB. Nodular lymphocyte predominant Hodgkin lymphoma: diagnostic pearls and pitfalls. Arch Pathol Lab Med. 2010;134(10):1434\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"4975_CR39","first-page":"45","volume":"30","author":"R Kuppers","year":"1997","unstructured":"Kuppers R, Roers A, Kanzler H. Molecular single cell studies of normal and transformed lymphocytes. Cancer Surv. 1997;30:45\u201358.","journal-title":"Cancer Surv"},{"issue":"5","key":"4975_CR40","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1080\/15321819.2014.1001031","volume":"36","author":"M Mlika","year":"2015","unstructured":"Mlika M, Helal I, Laabidi S, Braham E, El Mezni F. Is CD10 antibody useful in the diagnosis of angioimmunoblastic T-cell lymphoma? J Immunoassay Immunochem. 2015;36(5):510\u20136.","journal-title":"J Immunoassay Immunochem"},{"key":"4975_CR41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3389\/fimmu.2017.00961","volume":"8","author":"RM Gibbons Johnson","year":"2017","unstructured":"Gibbons Johnson RM, Dong H. Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells. Front Immunol. 2017;8:961.","journal-title":"Front Immunol."},{"issue":"2","key":"4975_CR42","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1182\/blood.V99.2.627","volume":"99","author":"A Attygalle","year":"2002","unstructured":"Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, Isaacson PG, Dogan A. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99(2):627\u201333.","journal-title":"Blood"},{"issue":"1","key":"4975_CR43","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/asheducation-2017.1.310","volume":"2017","author":"WR Liu","year":"2017","unstructured":"Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2017;2017(1):310\u20136.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"4975_CR44","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1038\/ncomms6997","volume":"6","author":"AR Khan","year":"2015","unstructured":"Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun. 2015;6:5997.","journal-title":"Nat Commun."},{"issue":"12","key":"4975_CR45","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","volume":"23","author":"Z Gatalica","year":"2014","unstructured":"Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2965\u201370.","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-04975-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-020-04975-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-04975-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T19:11:51Z","timestamp":1615057911000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-020-04975-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,7]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4975"],"URL":"https:\/\/doi.org\/10.1186\/s13104-020-04975-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22304\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22304\/v2","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,7]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of World Medical Association Declaration of Helsinki \u201cEthical Principles for Medical Research Involving Human Subjects\u201d and approved by the Institutional Review Board of the Institute for Hematopathology, Hamburg, Germany (approval No. 383). All patients were informed of the investigational nature of this study and provided their written informed consent. The samples were qualified as redundant clinical specimens that had been de-identified and unlinked from patient information.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}